National clinical audit of biological therapies – UK inflammatory bowel disease (IBD) audit

Reports | Published: 22 Sep 2016

The purpose of this audit is to measure the efficacy, safety and appropriate use of biological therapies in patients with IBD in the UK. The audit also aims to capture patients’ views on their quality of life at intervals during their treatment.

This is the fifth report of the biological therapy element of the UK IBD audit; all analyses within this report include only those patients who were newly started on biological therapies between 12 September 2011 (the start of data collection) and 29 February 2016. The data contained within this report have only been taken from completed submissions within the biological therapy audit web tool (www.ibdbiologicsaudit.org).

The full report is available to download below.

View full press release here

Don’t miss out. Sign up to be notified when this resource is updated and to receive updates about other related quality improvement resources, events and news from HQIP. Or you can  .


By continuing you agree to receive emails with updates and other information from HQIP and you are confirming you are over the age of 13.

Please read our privacy policy to understand how HQIP uses the information you provide, your use of HQIP’s website and your interaction with the marketing emails to improve the relevance of the communications we send you. You can unsubscribe at any time.

I have read and agree with the contents of the privacy policy.

National clinical audit of biological therapies – UK inflammatory bowel disease (IBD) audit